{"nctId":"NCT03334435","briefTitle":"A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis","startDateStruct":{"date":"2018-03-28","type":"ACTUAL"},"conditions":["Atopic Dermatitis"],"count":1645,"armGroups":[{"label":"Responders and Partial Responders (RPR)-Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Baricitinib","Drug: Placebo"]},{"label":"RPR-Bari 1-milligram (mg)","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"RPR-Bari 2-mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"RPR-Bari 4-mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"Non-responders (NR): Bari 1 mg to 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"NR: Bari 1 mg to 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"NR: Bari 2 mg to 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"NR: Bari 2 mg to 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"NR: Bari 4 mg to 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"NR: Placebo to Bari 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib","Drug: Placebo"]},{"label":"NR: Placebo to Bari 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Bari 1 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"Bari 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"Bari 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]},{"label":"Bari 2-mg Open-Label Addendum","type":"EXPERIMENTAL","interventionNames":["Drug: Baricitinib"]}],"interventions":[{"name":"Baricitinib","otherNames":["LY3009104"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Have participated in previous studies (JAHL, JAHM and JAIY) and met specific completion requirements for those studies, and do not meet any of the following Exclusions:\n\nExclusion Criteria:\n\n* Had investigational product permanently discontinued at any time during a previous Baricitinib study.\n* Had temporary investigational product interruption continue at the final study visit of a previous Baricitinib study and, in the opinion of the investigator, this poses an unacceptable risk for the participant's participation in the study\n\nOR\n\nHave not participated in previous studies (JAHL, JAHM and JAIY) and satisfy the following criteria:\n\nInclusion Criteria:\n\n* Have been diagnosed with moderate to severe Atopic Dermatitis for at least 12 months.\n* Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.\n* Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).\n* Agree to use emollients daily.\n\nExclusion Criteria:\n\n* Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory, or unstable skin disease that requires frequent hospitalizations and/or intravenous treatment for skin infections.\n* A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.\n* Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.\n* Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).\n* Have been treated with the following therapies:\n\n  * Monoclonal antibody for less than 5 half-lives prior to randomization.\n  * Received prior treatment with any oral Janus kinase (JAK) inhibitor.\n  * Received any parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.\n  * Have had an intra-articular corticosteroid injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization.\n* Have high blood pressure characterized by a repeated systolic blood pressure \\>160 millimeters of mercury (mm Hg) or diastolic blood pressure \\>100 mm Hg.\n* Have had major surgery within the past eight weeks or are planning major surgery during the study.\n* Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.\n* Have a history of recurrent (≥ 2) VTE or are considered at high risk of VTE as deemed by the investigator.\n* Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.\n* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.\n* Have specific laboratory abnormalities.\n* Have received certain treatments that are contraindicated.\n* Pregnant or breastfeeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Responder and Partial Responders (RPR): Percentage of Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of Investigator's Global Assessment (IGA) 0 or 1","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using non-responder imputation (NRI). All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.5","spread":null},{"groupId":"OG001","value":"46.7","spread":null},{"groupId":"OG002","value":"59.3","spread":null},{"groupId":"OG003","value":"48.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"31.1","spread":null},{"groupId":"OG002","value":"63.0","spread":null},{"groupId":"OG003","value":"37.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8","spread":null},{"groupId":"OG001","value":"35.6","spread":null},{"groupId":"OG002","value":"50.0","spread":null},{"groupId":"OG003","value":"40.0","spread":null}]}]}]},{"type":"PRIMARY","title":"RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved a Response of IGA 0 or 1","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":null},{"groupId":"OG001","value":"45.3","spread":null},{"groupId":"OG002","value":"31.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null},{"groupId":"OG001","value":"24.5","spread":null},{"groupId":"OG002","value":"30.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"30.2","spread":null},{"groupId":"OG002","value":"31.7","spread":null}]}]}]},{"type":"SECONDARY","title":"RPR: Percentage of Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of IGA 0, 1 or 2","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1/2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"77.8","spread":null},{"groupId":"OG002","value":"81.5","spread":null},{"groupId":"OG003","value":"72.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"81.5","spread":null},{"groupId":"OG003","value":"58.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":null},{"groupId":"OG001","value":"53.3","spread":null},{"groupId":"OG002","value":"72.2","spread":null},{"groupId":"OG003","value":"58.6","spread":null}]}]}]},{"type":"SECONDARY","title":"RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved a Response of IGA 0, 1, or 2","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1/2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"73.6","spread":null},{"groupId":"OG002","value":"63.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":null},{"groupId":"OG001","value":"49.1","spread":null},{"groupId":"OG002","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"54.7","spread":null},{"groupId":"OG002","value":"52.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Non Responders (NR): Percentage of Baricitinib NR Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of IGA 0, 1 or 2","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1/2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"47.6","spread":null},{"groupId":"OG003","value":"43.6","spread":null},{"groupId":"OG004","value":"40.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.2","spread":null},{"groupId":"OG001","value":"43.2","spread":null},{"groupId":"OG002","value":"44.0","spread":null},{"groupId":"OG003","value":"48.7","spread":null},{"groupId":"OG004","value":"39.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","spread":null},{"groupId":"OG001","value":"48.1","spread":null},{"groupId":"OG002","value":"44.0","spread":null},{"groupId":"OG003","value":"38.5","spread":null},{"groupId":"OG004","value":"41.0","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Baricitinib NR Participants From Combination Therapy Study (JAIY) Who Achieved a Response of IGA 0, 1 or 2","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1/2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"57.1","spread":null},{"groupId":"OG002","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"42.9","spread":null},{"groupId":"OG002","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"42.9","spread":null},{"groupId":"OG002","value":"28.2","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Baricitinib NR Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of IGA 0 or 1","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"23.5","spread":null},{"groupId":"OG002","value":"15.5","spread":null},{"groupId":"OG003","value":"17.9","spread":null},{"groupId":"OG004","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"12.3","spread":null},{"groupId":"OG002","value":"10.7","spread":null},{"groupId":"OG003","value":"16.7","spread":null},{"groupId":"OG004","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":null},{"groupId":"OG001","value":"12.3","spread":null},{"groupId":"OG002","value":"19.0","spread":null},{"groupId":"OG003","value":"15.4","spread":null},{"groupId":"OG004","value":"20.5","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Baricitinib NR Participants From Combination Therapy Study (JAIY) Who Achieved a Response of IGA 0 or 1","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"23.8","spread":null},{"groupId":"OG002","value":"15.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"19.0","spread":null},{"groupId":"OG002","value":"5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"RPR: Percentage of Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of Eczema Area and Severity Index (EASI)75","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI 75.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.3","spread":null},{"groupId":"OG001","value":"62.2","spread":null},{"groupId":"OG002","value":"70.4","spread":null},{"groupId":"OG003","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"46.7","spread":null},{"groupId":"OG002","value":"74.1","spread":null},{"groupId":"OG003","value":"51.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":null},{"groupId":"OG001","value":"51.1","spread":null},{"groupId":"OG002","value":"64.8","spread":null},{"groupId":"OG003","value":"51.4","spread":null}]}]}]},{"type":"SECONDARY","title":"RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved a Response of EASI 75","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI 75.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":null},{"groupId":"OG001","value":"67.9","spread":null},{"groupId":"OG002","value":"55.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":null},{"groupId":"OG001","value":"47.2","spread":null},{"groupId":"OG002","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":null},{"groupId":"OG001","value":"52.8","spread":null},{"groupId":"OG002","value":"42.9","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Baricitinib NR Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of EASI 75","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI 75.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"43.2","spread":null},{"groupId":"OG002","value":"38.1","spread":null},{"groupId":"OG003","value":"38.5","spread":null},{"groupId":"OG004","value":"26.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.2","spread":null},{"groupId":"OG001","value":"30.9","spread":null},{"groupId":"OG002","value":"31.0","spread":null},{"groupId":"OG003","value":"44.9","spread":null},{"groupId":"OG004","value":"30.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":null},{"groupId":"OG001","value":"35.8","spread":null},{"groupId":"OG002","value":"34.5","spread":null},{"groupId":"OG003","value":"34.6","spread":null},{"groupId":"OG004","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Baricitinib NR Participants From Combination Therapy Study (JAIY) Who Achieved a Response of EASI 75","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI 75.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"57.1","spread":null},{"groupId":"OG002","value":"28.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"28.6","spread":null},{"groupId":"OG002","value":"28.2","spread":null}]}]}]},{"type":"SECONDARY","title":"RPR: Percentage of Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved 4-Point Improvement in Itch Numeric Rating Scale (NRS)","description":"The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing \"no itch\" and 10 representing \"worst itch imaginable.\" Overall severity of a participants itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as NRS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6","spread":null},{"groupId":"OG001","value":"25.8","spread":null},{"groupId":"OG002","value":"32.6","spread":null},{"groupId":"OG003","value":"41.0","spread":null}]}]}]},{"type":"SECONDARY","title":"RPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved 4-Point Improvement in Itch NRS","description":"The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing \"no itch\" and 10 representing \"worst itch imaginable.\" Overall severity of a participants itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as NRS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null},{"groupId":"OG001","value":"45.8","spread":null},{"groupId":"OG002","value":"46.4","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Baricitinib NR Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved 4-Point Improvement in Itch NRS","description":"The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing \"no itch\" and 10 representing \"worst itch imaginable.\" Overall severity of a participants itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as NRS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"38.7","spread":null},{"groupId":"OG002","value":"24.3","spread":null},{"groupId":"OG003","value":"31.0","spread":null},{"groupId":"OG004","value":"22.5","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Baricitinib NR Participants From Combination Therapy Study (JAIY) Who Achieved 4-Point Improvement in Itch NRS","description":"The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing \"no itch\" and 10 representing \"worst itch imaginable.\" Overall severity of a participants itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as NRS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"36.8","spread":null},{"groupId":"OG002","value":"31.4","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Placebo NR Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of IGA 0, 1 or 2","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1/2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","spread":null},{"groupId":"OG001","value":"67.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.7","spread":null},{"groupId":"OG001","value":"62.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"57.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6","spread":null},{"groupId":"OG001","value":"46.9","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Placebo NR Participants From Combination Therapy Study (JAIY) Who Achieved a Response of IGA 0, 1 or 2","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1/2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"46.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":null},{"groupId":"OG001","value":"46.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":null},{"groupId":"OG001","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Placebo NR Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of IGA 0 or 1","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null},{"groupId":"OG001","value":"25.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"29.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"27.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"23.7","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Placebo NR Participants From Combination Therapy Study (JAIY) Who Achieved a Response of IGA 0 or 1","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as IGA 0/1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"17.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"10.7","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Placebo NR Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of EASI 75","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI 75.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":null},{"groupId":"OG001","value":"46.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"53.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"45.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null},{"groupId":"OG001","value":"38.7","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Placebo NR Participants From Combination Therapy Study (JAIY) Who Achieved a Response of EASI 75","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI 75.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":null},{"groupId":"OG001","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"32.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"32.1","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Placebo NR Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved 4-Point Improvement in Itch NRS","description":"The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing \"no itch\" and 10 representing \"worst itch imaginable.\" Overall severity of a participants itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as NRS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null},{"groupId":"OG001","value":"35.7","spread":null}]}]}]},{"type":"SECONDARY","title":"NR: Percentage of Placebo NR Participants From Combination Therapy Study (JAIY) Who Achieved 4-Point Improvement in Itch NRS","description":"The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing \"no itch\" and 10 representing \"worst itch imaginable.\" Overall severity of a participants itching is indicated by selecting the number, using a daily diary, that best describes the worst level of itching in the past 24 hours. The results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as NRS.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"26.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) and Week 104 in Randomized Withdrawal and Downtitration Substudy (Participants Entering the Substudy)","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null},{"groupId":"OG001","value":"60.7","spread":null},{"groupId":"OG002","value":"50.0","spread":null},{"groupId":"OG003","value":"92.4","spread":null},{"groupId":"OG004","value":"70.3","spread":null},{"groupId":"OG005","value":"44.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"48.8","spread":null},{"groupId":"OG002","value":"41.7","spread":null},{"groupId":"OG003","value":"83.7","spread":null},{"groupId":"OG004","value":"58.2","spread":null},{"groupId":"OG005","value":"33.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved a Response of IGA 0 or 1 Assessed at 16 Weeks After Rerandomization (Week 68) and Week 104 in Randomized Withdrawal and Downtitration Substudy (Participants Entering the Substudy)","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":null},{"groupId":"OG001","value":"45.2","spread":null},{"groupId":"OG002","value":"29.8","spread":null},{"groupId":"OG003","value":"47.8","spread":null},{"groupId":"OG004","value":"41.8","spread":null},{"groupId":"OG005","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null},{"groupId":"OG001","value":"35.7","spread":null},{"groupId":"OG002","value":"33.3","spread":null},{"groupId":"OG003","value":"42.4","spread":null},{"groupId":"OG004","value":"38.5","spread":null},{"groupId":"OG005","value":"21.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Response of EASI75 From Baseline of Originating Study Assessed at 16 Weeks After Rerandomization (Week 68) and Week 104 in Randomized Withdrawal and Downtitration Substudy (Participants Entering the Substudy)","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.\n\nThe results were analyzed using NRI. All participants who either discontinued the study treatment or discontinued the study for any reason at any time were defined as non-responders for the NRI analysis for categorical variables such as EASI 75.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.8","spread":null},{"groupId":"OG001","value":"58.3","spread":null},{"groupId":"OG002","value":"45.2","spread":null},{"groupId":"OG003","value":"73.9","spread":null},{"groupId":"OG004","value":"69.2","spread":null},{"groupId":"OG005","value":"44.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null},{"groupId":"OG001","value":"58.3","spread":null},{"groupId":"OG002","value":"41.7","spread":null},{"groupId":"OG003","value":"72.8","spread":null},{"groupId":"OG004","value":"58.2","spread":null},{"groupId":"OG005","value":"43.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Retreatment (Time to IGA ≥3) in Randomized Withdrawal and Down Titration (Participants Entering the Sub Study)","description":"Participants who entered the Substudy, relapsed with an IGA ≥3 and were retreated","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117.0","spread":null},{"groupId":"OG001","value":"56.0","spread":null},{"groupId":"OG002","value":"29.5","spread":null},{"groupId":"OG003","value":"61.0","spread":null},{"groupId":"OG004","value":"169.0","spread":null},{"groupId":"OG005","value":"30.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at 16 Weeks After Rerandomization (Week 68) and Week 104 in Randomized Withdrawal and Downtitration Substudy (Participants Entering the Substudy With IGA 0 or 1)","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"76.7","spread":null},{"groupId":"OG002","value":"72.1","spread":null},{"groupId":"OG003","value":"95.8","spread":null},{"groupId":"OG004","value":"89.6","spread":null},{"groupId":"OG005","value":"55.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"69.8","spread":null},{"groupId":"OG002","value":"62.8","spread":null},{"groupId":"OG003","value":"93.8","spread":null},{"groupId":"OG004","value":"77.1","spread":null},{"groupId":"OG005","value":"42.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response of IGA 0 or 1 Assessed at 16 Weeks After Rerandomization (Week 68) and Week 104 in Randomized Withdrawal and Downtitration Substudy (Participants Entering the Substudy With IGA 0 or 1)","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"69.8","spread":null},{"groupId":"OG002","value":"55.8","spread":null},{"groupId":"OG003","value":"70.8","spread":null},{"groupId":"OG004","value":"66.7","spread":null},{"groupId":"OG005","value":"36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.8","spread":null},{"groupId":"OG001","value":"55.8","spread":null},{"groupId":"OG002","value":"58.1","spread":null},{"groupId":"OG003","value":"60.4","spread":null},{"groupId":"OG004","value":"60.4","spread":null},{"groupId":"OG005","value":"32.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response of EASI75 From Baseline of Originating Study Assessed at 16 Weeks After Rerandomization(Week 68) and Week 104 in Randomized Withdrawal and Downtitration Substudy (Participants Entering Substudy With IGA 0 or 1)","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"76.7","spread":null},{"groupId":"OG002","value":"72.1","spread":null},{"groupId":"OG003","value":"83.3","spread":null},{"groupId":"OG004","value":"89.6","spread":null},{"groupId":"OG005","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null},{"groupId":"OG001","value":"74.4","spread":null},{"groupId":"OG002","value":"67.4","spread":null},{"groupId":"OG003","value":"83.3","spread":null},{"groupId":"OG004","value":"79.2","spread":null},{"groupId":"OG005","value":"55.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed Within 16 Weeks of Retreatment (Week 68) Randomized Withdrawal and Downtitration (Participants Retreated During Substudy)","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"74.5","spread":null},{"groupId":"OG002","value":"80.0","spread":null},{"groupId":"OG003","value":"57.1","spread":null},{"groupId":"OG004","value":"55.6","spread":null},{"groupId":"OG005","value":"76.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response of IGA 0 or 1 Assessed Within 16 Weeks of Retreatment (Week 68) Randomized Withdrawal and Downtitration (Participants Retreated During Substudy)","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"25.5","spread":null},{"groupId":"OG002","value":"44.0","spread":null},{"groupId":"OG003","value":"10.2","spread":null},{"groupId":"OG004","value":"26.7","spread":null},{"groupId":"OG005","value":"39.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Response of EASI75 From Baseline of Originating Study Assessed Within 16 Weeks of Retreatment (Week 68) Randomized Withdrawal and Downtitration (Participants Retreated During Substudy)","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":null},{"groupId":"OG001","value":"53.2","spread":null},{"groupId":"OG002","value":"70.0","spread":null},{"groupId":"OG003","value":"55.1","spread":null},{"groupId":"OG004","value":"44.4","spread":null},{"groupId":"OG005","value":"71.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response of IGA 0, 1, or 2 Assessed at Week 104 (Participants Not Entered Into Substudy)","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"45.6","spread":null},{"groupId":"OG002","value":"71.9","spread":null},{"groupId":"OG003","value":"51.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Response of IGA 0 or 1 Assessed at Week 104 (Participants Not Entered Into Substudy)","description":"The IGA measures the investigator's global assessment of the participant's overall severity of their atopic dermatitis (AD), based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification. All missing values were imputed using modified last observation carried forward (mLOCF).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"13.5","spread":null},{"groupId":"OG002","value":"53.1","spread":null},{"groupId":"OG003","value":"40.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Response of EASI75 From Baseline of Originating Study Assessed at Week 104 (Participants Not Entered Into Substudy)","description":"The EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100% and the severity of 4 clinical signs: (1) erythema, (2) edema/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head/neck, trunk, upper limbs, and lower limbs). Half scores are allowed between severities 1, 2, and 3. The final EASI score was obtained by weight-averaging these 4 scores and will range from 0 (no disease) to 72 (severe disease). The EASI75 is defined as a ≥ 75% improvement from baseline in the EASI score.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null},{"groupId":"OG001","value":"40.9","spread":null},{"groupId":"OG002","value":"65.6","spread":null},{"groupId":"OG003","value":"54.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":91},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Covid-19","Headache","Oral herpes"]}}}